Lexicon Pharmaceuticals
LXRX
123 hedge funds and large institutions have $344M invested in Lexicon Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 26 increasing their positions, 42 reducing their positions, and 17 closing their positions.
741% more call options, than puts
Call options by funds: $3.78M | Put options by funds: $450K
42% more capital invested
Capital invested by funds: $243M → $344M (+$101M)
6% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 17
0% more funds holding
Funds holding: 123 → 123 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.36% less ownership
Funds ownership: 70.57% → 70.21% (-0.36%)
38% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$2.99M |
| 2 |
Millennium Management
New York
|
+$2.48M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$786K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$761K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$615K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
-$4.26M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.85M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.25M |
| 4 |
HF
HRT Financial
New York
|
-$502K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$460K |
LXRX Hedge Fund Activity: Q3 2025 in Review
123 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q3 2025, worth a combined $344M — up 42% from $243M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new LXRX positions and 17 closed out — a net gain of 1 holder — while 26 added to existing stakes and 42 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $2.99M. The largest seller was Schonfeld Strategic Advisors, cutting an estimated $4.26M.
- 123 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $344M of Lexicon Pharmaceuticals stock for Q3 2025, up 42% quarter-over-quarter.
- 18 funds opened new Lexicon Pharmaceuticals positions in Q3 2025 and 17 closed out, a net change of +1 holder.
- The largest Lexicon Pharmaceuticals buyer in Q3 2025 was Citadel Advisors, an estimated $2.99M added.
- The largest Lexicon Pharmaceuticals seller in Q3 2025 was Schonfeld Strategic Advisors, an estimated $4.26M sold.
Based on aggregated 13F filings for Q3 2025.